2013 US Clinical Chemistry And Immunodiagnostics Markets
NEW YORK, Jan. 4, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
This new report from Venture Planning Group contains 600 pages, 120 tables and presents a comprehensive analysis of the US clinical chemistry and immunodiagnostics markets, including:
- Major issues pertaining to the US clinical chemistry and immunodiagnostic laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years.
- Five- and ten-year volume and sales forecasts for over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein and abused drug assays performed in US hospitals, commercial laboratories, and physician offices, including controls, calibrators and consumables.
- Five- and ten-year volume forecasts for serum, whole blood, plasma, CFS, urine and other specimens.
- Five- and ten-year reagent and instrument sales forecasts.
- Review of current instrumentation technologies, and a feature comparison of 50 high-, medium-, and low-volume/POC analyzers.
- Sales and market shares of leading reagent and instrument suppliers.
- Review of current and emerging technologies and their potential market applications.
- Product development opportunities for clinical chemistry and immunodiagnostic instruments and consumables.
- Profiles of 25 current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies.
- Market penetration strategies, entry barriers and risks.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts